Literature DB >> 24387210

Efficacy of combination treatment with cyclosporin A and corticosteroids for acute interstitial pneumonitis associated with dermatomyositis.

Kenji Nagasaka1, Masayoshi Harigai, Mutsuto Tateishi, Masako Hara, Yasuyuki Yoshizawa, Takao Koike, Nobuyuki Miyasaka.   

Abstract

Abstract Interstitial pneumonitis (IP) associated with polymyositis and dermatomyositis (PM/DM) is a serious complication that affects prognosis. We therefore undertook a retrospective multicenter study to examine the efficacy of a combination treatment with cyclosporin A (CsA) and corticosteroids. Fifty-three IP patients with PM/DM (9 PM, 44 DM) were analyzed. Thirty-two patients treated with CsA plus corticosteroids (9 PM, 23 DM) were included in the study. Four parameters, i.e., subjective symptoms, ausculatory sound, chest radiographs, and respiratory index, were serially evaluated. A general evaluation was performed 4 weeks after the start of the combination treatment. All patients with PM and chronic IP with DM, and 52% of those with acute IP with DM were graded as better than "partially effective" in the general evaluation. In contrast, all patients graded as "progressive" in the general evaluation had acute IP with DM. It is of note that in acute IP with DM, the survival rate of the group primarily treated with CsA and corticosteroids from the early stage of their disease was significantly higher than that of the group initially treated with corticosteroids alone (P = 0.049). In conclusion, a combination treatment of CsA and corticosteroids from the early stage of disease may be advantageous for patients with IP with PM/DM, especially acute IP with DM.

Entities:  

Year:  2003        PMID: 24387210     DOI: 10.3109/s10165-003-0205-1

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  6 in total

1.  Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease.

Authors:  Dong Jin Go; Jin Kyun Park; Eun Ha Kang; Hyun Mi Kwon; Yun Jong Lee; Yeong Wook Song; Eun Bong Lee
Journal:  Rheumatol Int       Date:  2015-07-30       Impact factor: 2.631

2.  Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia.

Authors:  Takuya Kotani; Tohru Takeuchi; Shigeki Makino; Kenichiro Hata; Shuzo Yoshida; Koji Nagai; Daisuke Wakura; Takeshi Shoda; Toshiaki Hanafusa
Journal:  Clin Rheumatol       Date:  2011-02-23       Impact factor: 3.650

3.  Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study.

Authors:  Katsuhiro Oda; Takuya Kotani; Tohru Takeuchi; Takaaki Ishida; Takeshi Shoda; Kentaro Isoda; Shuzo Yoshida; Yasuichiro Nishimura; Shigeki Makino
Journal:  Sci Rep       Date:  2017-05-09       Impact factor: 4.379

Review 4.  Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review.

Authors:  Caterina Vacchi; Marco Sebastiani; Giulia Cassone; Stefania Cerri; Giovanni Della Casa; Carlo Salvarani; Andreina Manfredi
Journal:  J Clin Med       Date:  2020-02-03       Impact factor: 4.241

5.  Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial.

Authors:  Kazuki Takada; Yoshinori Katada; Satoshi Ito; Taichi Hayashi; Jun Kishi; Kenji Itoh; Hiroyuki Yamashita; Michito Hirakata; Kimito Kawahata; Atsushi Kawakami; Norihiko Watanabe; Tatsuya Atsumi; Yoshinari Takasaki; Nobuyuki Miyasaka
Journal:  Rheumatology (Oxford)       Date:  2020-05-01       Impact factor: 7.580

6.  Choosing pharmacotherapy for ILD in patients with connective tissue disease.

Authors:  Zhe Wu; Philip L Molyneaux
Journal:  Breathe (Sheff)       Date:  2021-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.